Parallels between the development of therapeutic drugs and cancer health disparity programs: Implications for disparities reduction

Kenneth C. Chu, Moon S. Chen, Mark B. Dignan, Emmanuel Taylor, Edward Partridge, Terrance Albrecht, Claudia Baquet, Laura Beebe, Dedra Buchwald, Clayton Chong, Kathryn Coe, Graham Colditz, Mark Dignan, Paula A. Espinoza, Paul A. Godley, Margaret K. Hargreaves, James R. Hebert, Ronda Henry-Tillman, Elmer Huerta, Judith KaurHoward Koh, Grace X. Ma, Cathy D. Meade, Amelie Ramirez, David Satcher, Sora Park Tanjasiri, Beti Thompson, Victor Williams Tofaeono

    Research output: Contribution to journalArticle

    6 Scopus citations

    Abstract

    BACKGROUND. There are analogies between the development of therapeutic drugs for cancer and the development of interventions for reducing cancer health disparities. In both cases, it can take between 12 and 15 years for the benefits to become apparent. METHODS. The initial preclinical phase of drug development is analogous to the development of community partnerships and helping the community learn about cancer. The preclinical phase of in vitro and in vivo testing is analogous to identifying the disparities in the community. Then clinical testing begins with phase 1, toxicity, and dose-establishing studies. Analogously, community-based participatory research is used to develop disparities-reducing interventions (DRIs) within the community. RESULTS. The phase 2 clinical studies to determine whether the drug has activity are analogous to the DRI being implemented in the community to determine whether it can cause behavioral changes that will reduce cancer health disparities. If a drug passes phase 1 and 2 studies, phase 3 clinical trials are initiated. These are controlled studies to examine the efficacy of the drug. The similar activity for disparities research is to determine whether the DRI is better than the current standard/usual practice in controlled trials. If the drug is beneficial, the final phase is the dissemination and adoption of the drug. Analogously in disparities, if the DRI is beneficial, it is disseminated and is culturally adapted to other racial/ethnic groups and finally adopted as standard practice. CONCLUSIONS. The process of creating an effective DRI can be envisioned to have 4 stages, which can be used to aid in measuring the progress being made in reducing cancer health disparities.

    Original languageEnglish (US)
    Pages (from-to)2790-2796
    Number of pages7
    JournalCancer
    Volume113
    Issue number10
    DOIs
    StatePublished - Nov 15 2008

    Keywords

    • Cancer health disparity
    • Community-based participatory research
    • Disparities-reducing intervention
    • Information dissemination
    • Therapeutic drugs

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Parallels between the development of therapeutic drugs and cancer health disparity programs: Implications for disparities reduction'. Together they form a unique fingerprint.

  • Cite this

    Chu, K. C., Chen, M. S., Dignan, M. B., Taylor, E., Partridge, E., Albrecht, T., Baquet, C., Beebe, L., Buchwald, D., Chong, C., Coe, K., Colditz, G., Dignan, M., Espinoza, P. A., Godley, P. A., Hargreaves, M. K., Hebert, J. R., Henry-Tillman, R., Huerta, E., ... Tofaeono, V. W. (2008). Parallels between the development of therapeutic drugs and cancer health disparity programs: Implications for disparities reduction. Cancer, 113(10), 2790-2796. https://doi.org/10.1002/cncr.23879